By Colin Kellaher
BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study.
BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival.
BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker.
However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 03, 2025 06:34 ET (10:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。